To develop targeted leafl ets regarding cancer screening guidelines that take account the knowledge required by different target groups. METHODS: Before developing leafl ets, public interest data regarding cancer screening were collected by the problem solving model (the so-called KJ method developed for fi eld surveys in Japan). The KJ method includes two steps: label making of information corresponded to specifi c issues and grouping similar concepts. Contents of leafl ets were edited based on the results of the KJ methods but changed in the fi nal version according to discussions at a committee meeting involving public members. We compared the results of the KJ method and contents of the fi nal version of the leafl ets for the following groups: cervical cancer screening targeted at 20-year-old subjects (fi rst group), cervical cancer screening targeted at subjects aged 30 years and older (second group), and colorectal cancer screening targeted at subjects aged 40 years and older (third group). RESULTS: Common interests among the three groups included targeting cancer and screening methods. Although the KJ method revealed that the fi rst group expected broad information, in the fi nal version of the leafl et, only basic information regarding participation in cancer screening programs remained. The fi nal versions in group 2 and 3 almost corresponded to the fi rst interest of an actual plan to participate in a screening program including details of the screening methods as well as physical and fi nancial burden expected. Although information regarding the harm of cancer screening was initially included according to the results of the KJ methods in the second and third groups, there was no expectation in the fi rst group. CONCLUSIONS: A targeted leafl et is a powerful tool to share knowledge regarding cancer screening. We must understand the expectations of different target groups and prepare appropriate leafl ets that support the decision to take part in cancer screening.
PCN157 REASONS FOR DISCONTINUATION OF HORMONAL THERAPY IN BREAST CANCER PATIENTS ACROSS FIVE EUROPEAN COUNTRIES
Petrilla AA, Ferrufi no CP IMS Health, Falls Church, VA, USA OBJECTIVES: Recent evidence suggests that many breast cancer patients discontinue their hormonal therapy treatment regimen before the end of the recommended treatment period, but reasons for treatment discontinuation are not well understood. Therefore, we examined reasons for hormonal therapy discontinuation in a European treatment cohort of female breast cancer (BC) patients. METHODS: Female patients ages 21+ with a diagnosis of BC between January 2006 and December 2008 were identifi ed within IMS Oncology Analyzer TM which provides retrospective, cross-sectional, cancer-treatment data from 14 countries including France, Germany, Italy, Spain, and the United Kingdom and encompasses over 60,000 de-identifi ed BC patient records from a physician panel of nearly 800 doctors in the EU5. Patients within the EU5 with early-stage BC (stages I-IIIa) who received hormonal therapy and for whom their physician provided a reason for discontinuing fi rst course of therapy were included in the study. Patients enrolled in clinical trials were excluded. Reasons for discontinuation of therapy include course completion, progression of disease, stabilization of disease, adverse events, terminal outlook, poor performance, and patient's choice. RESULTS: 10,949 patients were identifi ed. Approximately 57.2% discontinued their fi rst course of hormonal therapy prior to course completion. Of these patients, the top reasons for early discontinuation included progression of the disease (59.5%), adverse events (21.7%) and patient choice (10.1%). Mean duration of therapy for all patients was 95.4 months (range 45.5-152.1). Time to discontinuation was signifi cantly shorter for those who quit due to Aes than those who quit by choice (36.2 months vs. 57.8 months, P < 0.0001). Of patients that discontinued due to AEs, hot fl ushes (46.1%), pain (19.1%), and nausea and vomiting (14.0%) were the most commonly reported events. CONCLUSIONS: This analysis in a real world setting provides new insight into reasons for early discontinuation of hormonal therapy in the EU5.
PCN158 TREATMENT DECISION CHANGE WITH 21-GENE RECURRENCE SCORE IN PATIENTS WITH EARLY STAGE BREAST CANCER (ESBC): A META-ANALYSIS
Chien R 1 , Hornberger J 2 1 Cedar Associates LLC, Menlo Park, CA, USA; 2 Cedar Associates LLC and Stanford University, Menlo Park, CA, USA OBJECTIVES: The 21-gene Recurrence Score® (RS) is a validated assay for estimating a woman's recurrence risk and chemotherapy benefi t after the diagnosis of estrogen receptor positive (ER+), ESBC. We conducted a meta-analysis of RS's infl uence on treatment recommendations/decisions in lymph node negative (LN-) disease. METHODS: Literature was abstracted on cohort studies that reported the change in the recommendation or actual use of adjuvant chemotherapy (CT) for patients with ER+, LN-, ESBC before and after the RS. Outcomes evaluated were: treatment decision change from 1) CT plus hormone therapy (HT) to HT-only or 2) HT-only to CT plus HT. Actual treatment change was used when available. Reductions in the relative and absolute CT use associated with the RS were computed with Review Manager (5 Version 5.0.24; Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration 2008). The relative change in CT was calculated as a before-to-after ratio of proportion of patients recommended or received CT, weighted by study sample size. RESULTS: Seven published studies (n = 912 patients) were eligible for the metaanalysis. One was a prospective physician survey; six were retrospective chart reviews. a total of 569 (62%) patients were recommended CT prior to RS testing. After RS testing, 272 (30%) patients were recommended or received CT. In six of seven studies (n = 652 patients) that reported a treatment change, 212 (32%) patients switched from CT plus HT before RS to HT-only after RS. The absolute reduction in CT before and after RS testing was 30% (95% CI [−39%, −21%]). The relative reduction in CT before and after RS was 49% (95% CI [42%, 58%]). Estimates varied little when analysis omitted a single study. Limitations include heterogeneity in study designs.
CONCLUSIONS:
The meta-analysis shows consistent overall reduction in CT with the use of RS. Retrospective claims databases are commonly used in outcomes research. Since physician charts are rarely available to confi rm diagnoses, care must be taken when choosing patient populations. OBJECTIVES: To show how patient selection criteria affects sample size and chemotherapy treatment rates using an ovarian cancer (OC) population. METHODS: Patients were initially selected if they met the following inclusion criteria: at least one diagnosis of OC (ICD-9-CM codes 183.0x) between 1/1/2002 and 12/31/2007 (fi rst OC diagnosis date termed index), 6 months pre-index and 12 months post-index eligibility, and no OC diagnosis in the 6 months pre-index. Additional criteria were imposed to further refi ne the sample and assess variations in chemotherapy treatment rates. First, patients were required to have at least two diagnoses of OC at least 14 days apart. Next, patients were required to have both OC diagnoses on a record labeled as medical, surgical, facility, or pharmacy (i.e., ancillary records were excluded). RESULTS: A total of 37,172 patients had at least one diagnosis of OC. Of those, 16,418 had 6 months pre-index and 12 months post-index eligibility with no pre-index OC diagnoses. In this population, 26% of patients received chemotherapy. When patients were also required to have one additional OC diagnosis at least 14 days from index, the sample size dropped to 7431 patients, of whom 47% received chemotherapy. When OC diagnoses on ancillary records were excluded, a total of 6213 patients were identifi ed, of whom 52% received chemotherapy. CONCLUSIONS: Chemotherapy rates among OC patients varied signifi cantly by the sample selection criteria used. Care must be taken to identify the correct patient sample in any retrospective database analysis since selection criteria affect the appropriateness of the sample, and thus the study results.
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PCN161 DECISION-ANALYTIC MODELING IN CHRONIC MYELOID LEUKEMIA-A SYSTEMATIC OVERVIEW
Rochau U 1 , Schwarzer R 1 , Sroczynski G 1 , Jahn B 1 , Wolf D 2 , Gastl G 2 , Siebert U 1 1 UMIT-University for Health Sciences, Medical Informatics and Technology; OncotyrolCenter for Personalized Cancer Medicine, Hall, Tyrol, Austria; 2 Medical University Innsbruck, Innsbruck, Austria OBJECTIVES: To provide an overview on published decision-analytic models evaluating various treatment strategies in chronic myeloid leukemia (CML). We sought to describe and analyze the structural and methodological approaches used and to derive recommendations for future CML models. METHODS: We performed a systematic literature review in electronic databases (Medline/PreMedline, EconLit, EMBASE, and others) to identify published studies evaluating CML treatment strategies using mathematical decision models. The models were required to compare different treatment strategies and to comprise relevant clinical health outcomes such as life-years gained or QALYs over a defi ned time horizon and population. We used standardized forms for data extraction, description of study design, methodological framework, and data sources. RESULTS: We identifi ed 14 different decision-analytic modeling studies, among which, 13 included economic evaluations. The modeling approaches varied substantially and comprised decision trees, Markov models, Monte Carlo simulations, and mathematical equations. Time horizons ranged from 2 years to lifetime. Health outcomes included survival, life expectancy, and QALYs. Compared treatment strategies comprised bone or blood marrow transplantation, conventional chemotherapy, interferon-alpha, and fi rst-generation tyrosine kinase inhibitor (TKI) imatinib. None of the models evaluated comprehensive personalized medicine strategies or second generation TKI (e.g., nilotinib, dasatinib). Only few models were validated using independent data. CONCLUSIONS: We found several well-designed models for different CML treatment strategies. However, the quality of reporting varied substantially. We recommend that future models should include novel treatment options, subgroup evaluations for a more personalized decision making, and validation using independent data. Already available models with a short time horizon could be updated with new survival data. Although any model should use empirical data if possible, the effects of treatments on long-term health outcomes are seldom observed within the follow-up time of a clinical study. Extrapolation over a lifetime horizon will generally be required in economic models where treatments have different cumulative survival at the end of the clinical trial. Typically, a within-trial analysis of costs and health effects, in which outcomes are truncated at the conclusion of the trial, will be overly conservative. OBJECTIVES: The purpose of this study is to compare different methods of extrapolation in the context of examples concerning oncology, although the principles apply across all therapeutic areas. METHODS: There is a set of standard assumptions regarding extrapolation of survival data from clinical studies, ranging from very cautious ("stop-and drop") to very optimistic ("continued benefi t"). The impact of different assumptions regarding extrapolation is explored, and the implications are discussed. CONCLUSIONS: The choice of extrapolation method has signifi cant impact on comparative clinical effects, costs, and cost-effectiveness. Based on our fi ndings and supporting examples, we propose the following: 1) Analysts should perform and report results under a range of specifi c standard extrapolation assumptions to increase comparability across studies.
PCN162 EXTRAPOLATION IN TRIAL-BASED COST-EFFECTIVENESS MODELING: IN SEARCH OF A STANDARD
2) The choice of a base-case approach in any particular study should be guided by knowledge about the biology of the indication under evaluation and the mechanism of action of the treatment. A case could be made for a reference case method of extrapolation, but we believe that sensitivity analysis across a standard set of possibilities is suffi cient. Adherence to these modeling practices will contribute to increased transparency in modeling and hence potentially to a greater confi dence among health-care decision-makers in the results from costeffectiveness analyses building on modeling and extrapolation. Challenges in analyzing cost data include addressing skewness in cost distributions, observed and unobserved heterogeneity across samples, and even more challenging complexities due to censoring. We combined generalized random effect models with inverse probability weighted (IPW) estimation techniques to address those challenges in a single model. METHODS: Generalized fi xed effect models have been used with weights that are calculated as inverse due to probability being uncensored. The Gaussian family and log link function was chosen and we applied a test to see if possibly censoring bias exists. We also calculated the deviation from the consistent value if standard pooled ordinary least squares were used. RESULTS: A total of 4824 observations were used in the analysis. We obtained Medicare claim fi les for the 2 years following patients' lung cancer diagnosis. Costs had high kurtosis and skewness. Moreover, 30% of the cases were censored, and therefore, their annual costs were not observed. The total cost of all care was $63,000 for the 2 years following a lung cancer diagnosis and $57,000 for incomplete cases. Results signifi cantly diverged from the standard regression model (P = 0.000). CONCLUSIONS: This paper applied inverse probability weighted estimation and fi xed effect panel data models to an inception cohort of patients newly diagnosed with lung cancer. Our fi ndings suggest that standard regression models yield inconsistent estimators due to censoring bias. The IPW least square estimation method removes that bias.
PCN163 EXTENDING FIXED EFFECT MODELS TO CENSORED COST DATA
PCN164 THE ECONOMICS OF CHRONIC MYELOGENOUS LEUKEMIA: A COMPARISON OF MODELING APPROACHES
Taylor MJ University of York, York, UK OBJECTIVES: Chronic myelogenous leukemia (CML) is a progressive disease which arises from damage to the DNA of a stem cell in the bone marrow. This results in the uncontrolled growth of white blood cells which, in turn, can lead to severe impairment of an individual's functioning. The National Institute for Health and Clinical Excellence (NICE) models the costs and benefi ts of medicines. The structure of these models is not prespecifi ed and wide variations are often observed, both in the model's choice of input parameters and in the structure of the modeling approach. While there is no such thing as a "correct" model, it is important that different models are compared and critiqued in order to identify any particular strengths and weaknesses of differing approaches. METHODS: A review was undertaken, identifying existing published models for CML. The data sources and choice of inputs were compared across each model and presented in a comparative table. Furthermore, the different approaches to model structure were examined, and attempts were made to explore the consequences of each approach on the models, costs, effectiveness, and cost-effectiveness fi ndings. RESULTS: The approaches to modeling CML vary signifi cantly between different studies. While different data sources are utilitized in each model, this can usually be explained by emerging data which were not available to other researchers. However, the overall approach to modeling the disease varied considerably across each study. Model structures and assumptions for long-term outcomes were key drivers of the cost-effectiveness results in each model, but were often based on contrasting and contradicting approaches. CONCLUSIONS: This review has highlighted signifi cant variation in approaches to modelling CML. It is recommended that longterm follow-up from previously published trials should be used to predict the likely outcomes associated with shorter-term outcomes, such as treatment response.
PCN165 INFLATION ANALYSIS AS A TOOL TO ASSESS COST-EFFECTIVENESS OF CANCER TREATMENT
Eliseeva E, Apanasevich V, Solodyankina T Vladivostok State Medical University, Vladivostok, Russia OBJECTIVES: Cost-effectiveness of chronic diseases drug-therapy is estimated with the help of various pharmacoeconomic analysis methods. Cost-effectiveness analysis, cost minimization analysis, cost-utility analysis, and cost-effectiveness analysis are used most often. We have proposed a modifi cation of the cost-effectiveness analysis, which makes possible to record patient's losses during treatment. Infl ation coeffi cient K and its average value-Kmed may be more reliable tool in assessing the costeffectiveness of treatment of recurrent disease. METHODS: Formula evaluation of the effectiveness can be expressed as Kt &die;T DC(M/Nt), where k-coeffi cient of effectiveness of treatment at time t DC-amount invested in the treatment of one person M-number of patients in the beginning of treatment (original group) N-number of patients at the time T t-regular interval, running on the account (month, day, year, etc.) RESULTS: Analysis of the coeffi cient K shows a tendency to increase with an increase in DC price for the treatment or-on decreasing the number of patients N, remaining in the group. As the period t becomes longer, entire formula is decreasing (infl ation). The average coeffi cient k meaning is calculated according the formula Kmed &die;T ∑ Kt/t. Coeffi cient shows the average cost of one free of recurrence month in one patient from the group. The number of patients in group N decreases as a disease recurs, which leads to Kmed increase because of reallocating funds spent on chronic patients for the rest of patients. CONCLUSIONS: The study of economic effi ciency through infl ationary coeffi cient K, we have proposed, is a sensitive method for estimating treatment costs, and may prove to be a reliable tool for cost-effectiveness analysis of chronic patient drug therapy.
PCN166 DEVELOPMENT OF A FLAG SYSTEM FOR THE COMPUTERIZED DETECTION OF CANCER PATIENTS WITH ADDITIONAL TREATMENT NEEDS BY MEANS OF THE "COMPUTER BASED HEALTH EVALUATION SYSTEM" (CHES)
Holzner B 1 , Kemmler G 1 , Giesinger J 1 , Gamper E 1 , Oberguggenberger A 1 , Zabernigg A 2 , Sperner-Unterweger B 1 1 Innsbruck Medical University, Innsbruck, Tyrol, Austria; 2 County Hospital Kufstein, Kufstein, Tyrol, Austria OBJECTIVES: Studies evaluating computer-aided routinely assessment of patientreported outcomes (PRO) suggest important benefi ts for physicians, patients, and their treatment. This project's aim was developing a fl ag system for computerized detection of cancer patients with additional treatment needs. METHODS: The detection system is part of the "Computer based Health Evaluation System (CHES)," a software for the computerized collection, processing, and presentation of PRO data. The fl ag system helps identify cancer patients with conspicuous subscale patterns. This includes cutoff values (patients marked with orange or red buttons) and signifi cant changes over time (yellow deltas). The testing data set was derived from a longitudinal study on QOL (assessed using the EORTC QLQ-C30) in chemotherapy patients at an oncological outpatient unit. Several criteria of "relevant" changes were compared regarding the prevalence of such changes in the study population and their statistical signifi cance on an individual patient level. RESULTS: QOL data of 167 cancer patients were analyzed (on average 5.3 assessments per patient). The 75th and 90th percentile showed to be useful cutoff values. Recommended thresholds of relevant QOL changes appear to be unduly low when considering changes in the individual patient. Based on empirical data, we suggest a modifi ed criterion of relevant change for the EORTC QLQ-C30 which appears clinically and statistically more meaningful. CONCLU-SIONS: The developed fl ag system enables physicians to detect patient-reported health defi cits (e.g., fatigue) at one glance. However, more research involving various diagnostic groups is needed for a more profound empirical basis for developing refi ned criteria.
